ApoB基因多态性对接受聚乙二醇干扰素α治疗的HBeAg阳性慢性乙型肝炎患者疗效的影响*

doi:10.3969/j.issn.1672-5069.2025.05.005

摘要/Abstract

摘要： 目的探讨载脂蛋白B(ApoB)基因多态性对聚乙二醇干扰素-α2b(peg-IFN-α2b)治疗的血清HBeAg阳性的慢性乙型肝炎(CHB)患者应答的影响。方法 2019年5月～2022年5月我院收治的血清HBeAg阳性CHB患者65例,均接受peg-IFN-α治疗48周。采用PCR法检测血清HBV DNA载量,采用电化学发光法检测血清HBsAg和HBeAg水平,采用Asian Screening Array芯片技术检测ApoB基因单核苷酸多态性(SNP)位点。应用多因素Logistic回归分析影响治疗应答的因素。结果在治疗48 w结束时,本组65例CHB患者获得完全应答(CR)25例(38.5%),部分应答(PR)40例(61.5%);CR组基线血清HBsAg和HBV DNA载量分别为(2.2±0.5)lg IU/mL和(6.1±1.5)lg IU/mL,均显著低于PR组【分别为(6.2±1.7)IU/mL和(7.1±1.3)lg IU/mL,P<0.05】,而血清ALT和AST水平分别为(134.6±17.6)U/L和(112.6±16.3)U/L,均显著高于PR组【分别为(62.6±14.8)U/L和(60.6±10.2)U/L,P<0.05】;在ApoB基因rs10199768基因,CR组AC基因型和A等位基因型占比分别为80.0%和60.0%,均显著高于PR组的37.5%和25.0%(P<0.05);在rs1367117基因,CR组GG基因型和G等位基因频率分别为28.0%和20.0%,均显著低于PR组的67.5%和60.0%,差异均具有统计学意义(P<0.05);多因素Logistic回归分析显示,rs10199768和rs1367117基因多态性是接受peg-IFN-α治疗的HBeAg阳性CHB患者应答的独立影响因素(OR=5.078,OR=4.933,均P<0.05)。结论影响peg-IFN-α治疗HBeAg阳性CHB患者应答的因素可能很多,开展ApoB基因多态性监测无疑提供了一个崭新的研究方向。

关键词: 乙型肝炎, 聚乙二醇干扰素-α2b, 载脂蛋白B, 基因多态性, 治疗, 应答

Abstract: Objective This study was conducted to explore impact of apolipoprotein B (ApoB) gene polymorphisms on response to pegylated interferon alpha-2b (peg-IFN-α2b) treatment in patients with serum HBeAg-positive chronic hepatitis B (CHB). Methods Sixty-five serum HBeAg-positive patients with CHB were encountered in our hospital between May 2019 and May 2022, and all received peg- IFN-α2b antiviral treatment for 48 weeks. Serum HBsAg and HBeAg, and HBV DNA loads were routinely assayed, and single nucleotide polymorphism (SNP) of ApoB gene was determined by gene chip. Multivariate Logistic regression analysis was applied to predict impacting factors. Results By end of 48-week antiviral treatment, complete response (CR) was 38.5% and partial response (PR) was 61.5%; baseline serum HBsAg and HBV DNA loads in patients with CR were (2.2±0.5)lg IU/mL and (6.1±1.5)lg IU/mL, both significantly lower than [(6.2±1.7)lg IU/mL and (7.1±1.3)lg IU/mL, respectively, P<0.05], while serum ALT and AST levels were (134.6±17.6)U/L and (112.6±16.3)U/L, both significantly higher than [(62.6±14.8)U/L and (60.6±10.2)U/L, respectively, P<0.05] in those with PR; as for ApoB gene rs10199768 locus, percentage of AC genotype and A allele frequencies in patients with CR were 80.0% and 60.0%, both significantly higher than 37.5% and 25.0%(P<0.05) in those with PR; as for rs1367117 gene, percentage of GG genotype and G allele frequencies in patients with CR were 28.0% and 20.0%, both significantly lower than 67.5% and 60.0% in those with PR (P<0.05); multivariate Logistic regression analysis showed that rs10199768 and rs1367117 SNP were independent factors impacting response to peg-IFN-α2b treatment in patients with serum HBeAg positive CHB (OR=5.078, OR=4.933, both P<0.05). Conclusion SNP of ApoB gene might impact response to peg-IFN-α2b antiviral treatment in patients with serum HBeAg positive CHB, and needs further clinical verification.

Key words: Hepatitis B, Pegylated interferon alpha-2b, Apolipoprotein B gene, Polymorphism, Therapy, Response

陈文哲, 王清园, 陈天, 许宇文. ApoB基因多态性对接受聚乙二醇干扰素α治疗的HBeAg阳性慢性乙型肝炎患者疗效的影响^*[J]. 实用肝脏病杂志, 2025, 28(5): 659-662.

Chen Wenzhe, Wang Qingyuan, Chen Tian, et al. Impact of apolipoprotein B gene polymorphisms on response to pegylated interferon alpha-2b treatment in patients with serum HBeAg-positive chronic hepatitis B[J]. Journal of Practical Hepatology, 2025, 28(5): 659-662.

参考文献

[1] 李子月, 杨士田, 吴玲玲, 等. HBV相关慢加急性肝衰竭患者预后危险因素分析及预后模型建立. 中华传染病杂志, 2019, 37(12): 737-741.
[2] 王禅, 秦伟, 戴勇, 等. 自体外周血干细胞移植治疗乙型肝炎肝硬化患者临床疗效及其对外周血T淋巴细胞亚群的影响. 实用肝脏病杂志, 2019, 22(1): 97-100.
[3] Tan M, Bhadoria AS, Cui F, et al. Estimating the proportion of people with chronic hepatitis b virus infection eligible for hepatitis b antiviral treatment worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2021, 6(2): 106-119.
[4] Le Bert N, Gill US, Hong M, et al. Effects of hepatitis b surface antigen on virus-specific and globalT cells in patients with chronic hepatitis B virus infection. Gastroenterology, 2020, 159(2): 652-664.
[5] Kawanaka M, Nishino K, Kawamoto H, et al. HepatitisB: who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases. World J Gastroenterol, 2021, 27(43): 7497-7508.
[6] Yin GQ, Li J, Zhong B, et al. New therapeutic options for persistent low-level viremia in patients with chronic hepatitis b virus infection: increase of entecavir dosage. World J Gastroenterol, 2021, 27(8): 666-676.
[7] Mohareb AM, Liu AF, Kim AY, et al. Clearance of hepatitisB e antigen in untreated chronic hepatitis b virus infection: a systematic review and meta-analysis. J Infect Dis, 2022, 226(10): 1761-1770.
[8] Duberg AS, Lybeck C, Fält A, et al. Chronic hepatitisB virus infection and the risk of hepatocellular carcinoma by age and country of origin in people living in sweden: a national register study. Hepatol Commun, 2022, 6(9): 2418-2430.
[9] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2022年版).实用肝脏病杂志,2023,26(3)S18-39.
[10] Xu C, Bao Y, Zuo J, et al. Maternal chronic hepatitis b virus infection and the risk of preterm birth: a retrospective cohort analysis inChinese women. J Viral Hepat, 2021, 28(10): 1422-1430.
[11] Chen J, Hubbard A, Bagley L, et al. Prevalence of latent tuberculosis infection among persons with chronic hepatitis b virus Infection: a systematic review and meta-analysis. Dig Dis Sci, 2022, 67(6): 2646-2654.
[12] Kumar A, Rajani D, Kumar S. Letter to the editor: hepatitisB virus genotype: a significant risk factor in determining which patients with chronic hepatitis B virus infection should undergo surveillance for hepatocellular carcinoma: the hepatitis B Alaska study. Hepatology, 2022, 76(3): 63-64.
[13] Yuen MF, Zhou X, Gane E, et al. Safety, pharmacokinetics, and antiviral activity of ro7049389, a core protein allosteric modulator, in patients with chronic hepatitisB virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial. Lancet Gastroenterol Hepatol, 2021, 6(9): 723-732.
[14] Lim SG, Baumert TF, Boni C, et al.The scientific basis of combination therapy for chronic hepatitis B functional cure. Nat Rev Gastroenterol Hepatol,2023,20(4):238-253.
[15] Mak LY, Wong D, Kuchta A, et al. HepatitisB virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B. Clin Mol Hepatol, 2023, 29(1): 146-162.
[16] Wang MD, Tang SC, Li C, et al. Aso visual abstract: association of concurrent metabolic syndrome with long-term oncological prognosis following liver resection for hepatocellular carcinoma among patients with chronic hepatitisB virus infection-a multicenter study of 1753 patients. Ann Surg Oncol, 2023, 30(1): 361-362.
[17] Terrault NA, Lok AS, Wahed AS, et al. Randomized trial of tenofovir with or without peginterferon alfa followed by protocolized treatment withdrawal in adults with chronic hepatitis B. Am J Gastroenterol, 2023,118(7):1214-1225.
[18] Wong GLH, Wong VWS. Dynamic change ofLSM-HCC score and enhanced liver fibrosis score to predict hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral treatment: abridged secondary publication. Hong Kong Med J, 2022, 28(1): 11-13.
[19] Hur M, Park M, Moon HW, et al. Comparison of non-invasive clinical algorithms for liver fibrosis in patients with chronic hepatitisB to reduce the need for liver biopsy: application of enhanced liver fibrosis and mac-2 binding protein glycosylation isomer. Ann Lab Med, 2022, 42(2): 249-257.
[20] Chotiyaputta W, Poosanasuwansri K, Kiattisunthorn K, et al. Comparison of viral control between two tenofovir dose reduction regimens (300 mg every 48 hours versus 300 mg every 72 hours) in chronic hepatitisB patients with moderate renal impairment from tenofovir-induced renal dysfunction. J Viral Hepat, 2021, 28(2): 364-372.

ApoB基因多态性对接受聚乙二醇干扰素α治疗的HBeAg阳性慢性乙型肝炎患者疗效的影响^*

Impact of apolipoprotein B gene polymorphisms on response to pegylated interferon alpha-2b treatment in patients with serum HBeAg-positive chronic hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	中华医学会肝病学分会重型肝病与人工肝学组, 中华医学会肝病学分会终末期肝病营养与再生学组. 慢加急性肝衰竭诊治指南(2025 年版)[J]. 实用肝脏病杂志, 2025, 28(5): 641-647.
[2]	丛东威, 刘丽娜, 高文娟, 黄超群. 干扰素α-2b联合恩替卡韦与干扰素α-2b联合替诺福韦治疗HBeAg阳性慢性乙型肝炎患者疗效比较研究^*[J]. 实用肝脏病杂志, 2025, 28(5): 655-658.
[3]	汤洁, 姜正伟, 周冰清, 蒋蓓莉, 张睿. 超声剪切波弹性成像检查联合APRI和FIB-4诊断血清HBeAg阳性慢性乙型肝炎患者肝纤维化程度价值研究^*[J]. 实用肝脏病杂志, 2025, 28(5): 663-666.
[4]	袁铃, 姜霞, 孙美杰, 岳冬黎, 张晓玲. 艾米替诺福韦与丙酚替诺福韦挽救治疗低病毒血症的慢性乙型肝炎患者临床研究^*[J]. 实用肝脏病杂志, 2025, 28(5): 667-670.
[5]	汤勤, 华忠, 苏麒麟, 陈小林. 艾米替诺福韦联合鳖甲煎丸治疗慢性乙型肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2025, 28(5): 671-674.
[6]	郝帅, 王梓依, 张心怡, 张粉娜, 苏娜, 贺娜. 常态化随访实施院内丙型肝炎微消除策略效果评价^*[J]. 实用肝脏病杂志, 2025, 28(5): 675-678.
[7]	刘志东, 李文松, 高震, 孙李妍, 丁琪. 达拉他韦和阿舒瑞韦治疗初治的基因1b型慢性丙型肝炎患者疗效及其外周血淋巴细胞亚群的变化^*[J]. 实用肝脏病杂志, 2025, 28(5): 679-682.
[8]	辛文渊, 李玉薇, 吴君. 达卡他韦联合阿舒瑞韦治疗基因1b型慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(5): 683-686.
[9]	张磊, 王亚茹, 李会平, 王帅, 张威, 周正, 张帆. 司美格鲁肽治疗2型糖尿病合并非酒精性脂肪性肝炎患者临床初步研究[J]. 实用肝脏病杂志, 2025, 28(5): 699-702.
[10]	王霞, 段旺旺, 李梦辉. 艾塞那肽联合多烯磷脂酰胆碱治疗酒精性肝炎患者初步疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(5): 715-718.
[11]	刘立华, 尤晓红, 范周红. 多烯磷脂酰胆碱联合水飞蓟素治疗102例药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(5): 723-726.
[12]	朱颖静, 吴洁, 田鑫越, 田巍巍. 内镜下组织胶注射治疗乙型肝炎肝硬化食管胃底静脉曲张破裂出血患者疗效分析^*[J]. 实用肝脏病杂志, 2025, 28(5): 731-734.
[13]	陈洁, 杨才敏, 彭彩玲, 徐辉. 基于北京PIR分型标准评价恩替卡韦治疗乙型肝炎肝硬化患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(5): 735-738.
[14]	穆亚, 葛乃建, 刘学, 王向东, 徐伟, 杨业发. TACE联合贝伐珠单抗和信迪利单抗治疗不可切除肝细胞癌患者临床疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(5): 751-754.
[15]	张小昭, 雷凯, 祁亚斌, 金雷, 朱代华. 阿替利珠单抗联合靶向药物和TACE术治疗中晚期原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(5): 759-762.